Benefit of prasugrel administration was observed consistently in insulin-treated patients (14.3% versus 22.2%, p < 0.01), as well as in T2D patients without insulin therapy (11.5% versus 15.3%, p < 0.01). Here, INS is linked to type 2 diabetes mellitus.